PT - JOURNAL ARTICLE AU - Rabeeyah Ahmed AU - Russell J. de Souza AU - Vincent Li AU - Sonia S. Anand TI - Assessing non-white ethnic participation in type 2 diabetes mellitus randomized clinical trials: A Meta-Analysis AID - 10.1101/2022.06.28.22275821 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.28.22275821 4099 - http://medrxiv.org/content/early/2022/06/29/2022.06.28.22275821.short 4100 - http://medrxiv.org/content/early/2022/06/29/2022.06.28.22275821.full AB - Importance The prevalence of type 2 diabetes mellitus (T2DM) is increasing globally, and the greatest burden is borne by non-white ethnic groups. Randomized clinical trials (RCTs) provide evidence regarding the optimal medical therapy for the treatment of T2DM patients and inform national and international guidelines. However, there are concerns that the enrollment of ethnically diverse people into these trials is limited, which has resulted in a lack of ethnic diversity in RCTs of T2DM. Furthermore, the extent of underrepresentation may differ according to whether a trial is government-funded or industry-funded.Objective To systematically review and meta-analyze the proportion of non-white and white participants relative to their disease burden of T2DM included in large, influential government- and industry-funded RCTs of T2DM pharmacotherapies.Data Sources The PubMed electronic database was searched from January 2000 through January 2021.Study Selection Reports of RCTs of T2DM medications with a total sample size of at least 100 participants published in the year 2000 onwards, in high impact general medical journals (i.e., impact factor >10), were included.Data Extraction and Synthesis Data including the number of participants, proportion of participants by ethnicity, and funding sources, were extracted from trial reports.Main Outcomes and Measures The main outcome was the participation-to-prevalence ratio (PPR), which was calculated for each trial by dividing the percentage of white and non-white participants in the trial by the percentage of white and non-white participants with T2DM for the countries or regions of recruitment represented in each trial. A random-effects meta-analysis was used to generate the pooled PPR and 95% confidence intervals (CI) across study types. A PPR <0.80 indicates underrepresentation and >1.20 indicates overrepresentation.Results A total of 82 trials were included involving 296,964 participants: 14 were government-funded trials, and 68 were industry-funded trials. For government trials, the PPR for white participants was 1.11 (95% CI; 1.00-1.23) and for non-white participants was 0.73 (95% CI:0.62-0.86). Among industry trials, the PPR for white participants was 2.19 (95%CI: 1.91-2.50), and the PPR for non-white participants was 0.33 (95%CI: 0.29-0.38). Heterogeneity was high across all PPRs.Conclusions and Relevance Non-white participants are underrepresented in both government- and industry-funded T2DM trials, compared to white participants. The greatest disparity in ethnic diversity in RCTs is observed for industry-funded trials.Question What is the representation of non-white participants in type 2 diabetes randomized clinical trials relative to their disease burden?Findings In this meta-analysis, non-white participants are underrepresented in both government-and industry-funded type 2 diabetes randomized trials, compared to white participants. The greatest disparity in ethnic diversity in randomized trials was observed for those funded by industry.Meaning Deliberate strategies to improve recruitment and enrolment of diverse participants proportional to the type 2 diabetes disease burden into industry and government-funded randomized controlled trials are needed to enhance the generalizability of research findings.Competing Interest StatementDr. de Souza has served as an external resource person to the World Health Organization's Nutrition Guidelines Advisory Group on trans fats, saturated fats, and polyunsaturated fats. The WHO paid for his travel and accommodation to attend meetings from 2012-2017 to present and discuss this work. He has also done contract research for the Canadian Institutes of Health Research's Institute of Nutrition, Metabolism, and Diabetes, Health Canada, and the World Health Organization for which he received remuneration. He has received speaker's fees from the University of Toronto, and McMaster Children's Hospital. He has held grants from the Canadian Institutes of Health Research, Canadian Foundation for Dietetic Re-search, Population Health Research Institute, and Hamilton Health Sciences Corporation as a principal investigator, and is a co-investigator on several funded team grants from the Canadian Institutes of Health Research. He serves as a member of the Nutrition Science Advisory Committee to Health Canada (Government of Canada), and a co-opted member of the Scientific Advisory Committee on Nutrition (SACN) Subgroup on the Framework for the Evaluation of Evidence, and as an independent director of the Helderleigh Foundation (Canada).Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.